Extended Data Fig. 3: Efficiency of CCR5KI-CAR19 KO/KI expanded with APCs and killing dynamics. | Nature Biomedical Engineering

Extended Data Fig. 3: Efficiency of CCR5KI-CAR19 KO/KI expanded with APCs and killing dynamics.

From: CCR5-targeted allogeneic gamma–delta CD19 chimeric antigen receptor T cells for HIV-associated B cell-malignancy immunotherapy

Extended Data Fig. 3: Efficiency of CCR5KI-CAR19 KO/KI expanded with APCs and killing dynamics.The alternative text for this image may have been generated using AI.

a, Summary of CCR5KI-CAR19 and CCR5-KO in αβ mock (light red) and CCR5KI-CAR19 (red, n = 9) T cells, γδ mock (light blue, n = 9) and CCR5KI-CAR19 (blue, n = 12) T cells and γδ mock (light purple, n = 8) and CCR5KI-CAR19 (purple, n = 8) T cells culture with antigen-presenting cells (APCs, two-tailed Kruskal–Wallis test, n indicates different donors). b Summary of CCR5-KO in αβ mock (light red, n = 9) and CCR5KI-CAR19 (red, n = 9) T cells, γδ mock (light blue, n = 9) and CCR5KI-CAR19 (blue, n = 12) T cells, and γδ mock (light purple, n = 5) and CCR5KI-CAR19 (purple, n = 8) T cells cultured with APCs (two-tailed Kruskal–Wallis test; n indicates independent donors). c, Cytolytic activity of αβ mock (light red) and CCR5KI-CAR19 (red) T cells, and γδ mock* (light purple) and CCR5KI-CAR19* (purple) T cells, measured 24 h after co-culture (two-tailed Mann–Whitney U test; n = 4 per group; n indicates independent donors). Data are presented as mean ± SD from different donors. Asterisk (*) indicates expansion with APCs.

Back to article page